3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 4
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
2768
Triple Negative Breast Neoplasms
406
Neoplasm Metastasis
156
Breast Neoplasms, Male
102
Neoplasms
100
Ovarian Neoplasms
69
Carcinoma, Non-Small-Cell Lung
68
Carcinoma, Intraductal, Noninfiltrating
68
Lung Neoplasms
66
Brain Neoplasms
60
Colorectal Neoplasms
52
Inflammatory Breast Neoplasms
50
Advanced Breast Cancer
49
Breast Carcinoma In Situ
47
Prostatic Neoplasms
42
Melanoma
38
Pancreatic Neoplasms
37
Stomach Neoplasms
32
Uterine Cervical Neoplasms
28
Sarcoma
27
HER2-positive Breast Cancer
27
Endometrial Neoplasms
25
Head and Neck Neoplasms
24
Recurrence
23
Colonic Neoplasms
22
Carcinoma, Renal Cell
21
Carcinoma, Ovarian Epithelial
21
Small Cell Lung Carcinoma
20
Multiple Myeloma
20
Carcinoma, Ductal, Breast
20
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Second Primary
×
Breast
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts